Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | CASR | P41180 | 3/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | MMP12 | P39900 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | F10 | P00742 | 1/20 | 0.39 |
| ▸ | F7 | P08709 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4357426 | 0.77 | MMP12 (0.43) | HPGDALDH1A1MAPTKMT2AMMP12 | |
| SCHEMBL5651545 | 0.76 | MMP12 (0.44) | HPGDALDH1A1MAPTMMP12 | |
| SCHEMBL2247828 | 0.75 | MMP12 (0.42) | HPGDALDH1A1MAPTMMP12 | |
| SCHEMBL2247308 | 0.75 | TRPM8 (0.43) | HPGDALDH1A1MAPTMMP12 | |
| SCHEMBL4358333 | 0.73 | PPARD (0.42) | HPGDALDH1A1MAPTKMT2AMMP12 | |
| SCHEMBL2246642 | 0.72 | MMP12 (0.41) | HPGDALDH1A1MAPTMMP12 | |
| SCHEMBL4363950 | 0.72 | MMP12 (0.42) | ALDH1A1KMT2AMMP12 | |
| SCHEMBL4369489 | 0.72 | PTGES (0.45) | HPGDALDH1A1MAPTKMT2AMMP12 | |
| SCHEMBL5654170 | 0.72 | MMP12 (0.41) | HPGDALDH1A1MAPTKMT2AMMP12 | |
| SCHEMBL2249544 | 0.71 | MMP12 (0.39) | HPGDALDH1A1MAPTMMP12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7553873-B2 | Glutamate aggrecanase inhibitors | WYETH (US) | 2009-06-30 | — | — | US | disclosed |
| US-20070043066-A1 | Glutamate aggrecanase inhibitors | WYETH (US) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043066-A1 | Glutamate aggrecanase inhibitors | ADAMTS5, ADAMTS1, ADAMTS7 | CD274 2367/4885HPGD 1335/4885ALDH1A1 991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.